SNSS stock went parabolic Thursday afternoon just days after the company announced positive drug data. SNSS announces positive data from two Phase 2 clinical trials of the Company’s lead drug candidate, voreloxin. We are expecting a gap up Friday with a short term price target of $2.10. StockPreacher.com also announces an investment report featuring Sunesis Pharmaceuticals Inc. The full report is available at: http://www.stockpreacher.com/n/SNSS
Market Club has a very interesting take on how SNSS is playing out after the past volume surge. The “Trade Triangles” paint the picture. CLICK HERE and just enter the ticker (SNSS) your name and e-mail address for the FREE No strings Attached Report sent realtime to your in-box!
